The anti-proliferation mechanism of glucocorticoid mediated by glucocorticoid receptor-regulating gene expression

Pathophysiology

Volumn 16, Issue 4, 2009, Pages 267-272

  Lu, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Glucocorticoid; Glucocorticoid receptor; RhoB; Type II TGF receptor

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; NEUTRALIZING ANTIBODY; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE TARGETING; HORMONE ACTION; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; RNA INTERFERENCE; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 69249211234     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2009.02.009     Document Type: Article

References (39)

1. Frankfurt O., and Rosen S.T. Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr. Opin. Oncol. 16 (2004) 553-563
2. Crochemore C., Michaelidis T.M., Fischer D., Loeffler J.P., and Almeida O.F. Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation. FASEB J. 16 (2002) 761-770
3. Horsch K., de Wet H., Schuurmans M.M., Allie-Reid F., Cato A.C., Cunningham J., Burrin J.M., Hough F.S., and Hulley P.A. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol. Endocrinol. 21 (2007) 2929-2940
4. Yamamoto T., Nishiguchi M., Inoue N., Goto H.G., Kudawara I., Ueda T., Yoshikawa H., Tanigaki Y., and Nishizawa Y. Inhibition of murine osteosarcoma cell proliferation by glucocorticoid. Anticancer Res. 22 (2002) 4151-4156
5. Cha H.H., Cram E.J., Wang E.C., Huang A.J., Kasler H.G., and Firestone G.L. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells. J. Biol. Chem. 273 (1998) 1998-2007
6. Greenberg A.K., Hu J., Basu S., Hay J., Reibman J., Yie T.A., Tchou-Wong K.M., Rom W.N., and Lee T.C. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators. Am. J. Respir. Cell Mol. Biol. 27 (2002) 320-328
7. Ferrandina G., Scambia G., Benedetti Panici P., Bonanno G., De Vincenzo R., Rumi C., Bussa S., Genuardi M., Romano Spica V., and Mancuso S. Effects of dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian cancer cells. Mol. Cell. Endocrinol. 83 (1992) 183-193
8. Goya L., Maiyar A.C., Ge Y., and Firestone G.L. Glucocorticoids induce a G1/G0 cell cycle arrest of Con8 rat mammary tumor cells that is synchronously reversed by steroid withdrawal or addition of transforming growth factor-alpha. Mol. Endocrinol. 7 (1993) 1121-1132
9. Nishimura K., Nonomura N., Satoh E., Harada Y., Nakayama M., Tokizane T., Fukui T., Ono Y., Inoue H., Shin M., Tsujimoto Y., Takayama H., Aozasa K., and Okuyama A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J. Natl. Cancer Inst. 93 (2001) 1739-1746
10. Saunders D.E., Christensen C., Wappler N.L., Schultz J.F., Lawrence W.D., Malviya V.K., Malone J.M., and Deppe G. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 4 (1993) 201-208
11. Fakih M., Johnson C.S., and Trump D.L. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60 (2002) 553-561
12. Koutsilieris M., Mitsiades C.S., Bogdanos J., Dimopoulos T., Karamanolakis D., Milathianakis C., and Tsintavis A. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin. Cancer Res. 10 (2004) 4398-4405
13. Nishimura K., Nonomura N., Yasunaga Y., Takaha N., Inoue H., Sugao H., Yamaguchi S., Ukimura O., Miki T., and Okuyama A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89 (2000) 2570-2576
14. De Nijs R.N. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med. 99 (2008) 23-43
15. Chrousos G.P., and Kino T. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci. STKE 2005 (2005) e48
16. Adcock I.M., Caramori G., and Ito K. New insights into the molecular mechanisms of corticosteroids actions. Curr. Drug Targets 7 (2006) 649-660
17. Hayashi R., Wada H., Ito K., and Adcock I.M. Effects of glucocorticoids on gene transcription. Eur. J. Pharmacol. 500 (2004) 51-62
18. Heitzer M.D., Wolf I.M., Sanchez E.R., Witchel S.F., and DeFranco D.B. Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord. 8 (2007) 321-330
19. Bladh L.G., Liden J., Dahlman-Wright K., Reimers M., Nilsson S., and Okret S. Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. Mol. Pharmacol. 67 (2005) 815-826
20. Leis H., Page A., Ramirez A., Bravo A., Segrelles C., Paramio J., Barettino D., Jorcano J.L., and Perez P. Glucocorticoid receptor counteracts tumorigenic activity of Akt in skin through interference with the phosphatidylinositol 3-kinase signaling pathway. Mol. Endocrinol. 18 (2004) 303-311
21. Miller A.L., Webb M.S., Copik A.J., Wang Y., Johnson B.H., Kumar R., and Thompson E.B. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol. Endocrinol. 19 (2005) 1569-1583
22. Nuutinen U., Postila V., Matto M., Eeva J., Ropponen A., Eray M., Riikonen P., and Pelkonen J. Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line. Exp. Cell Res. 312 (2006) 322-330
23. Xia B., Lu J., and Wang G. Glucocorticoid modulation of extracellular signal-regulated protein kinase 1/2 and p38 in human ovarian cancer HO-8910 cells. Chin. Med. J. (Engl) 116 (2003) 753-756
24. Sengupta S., and Wasylyk B. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann. NY Acad. Sci. 1024 (2004) 54-71
25. Sundberg M., Savola S., Hienola A., Korhonen L., and Lindholm D. Glucocorticoid hormones decrease proliferation of embryonic neural stem cells through ubiquitin-mediated degradation of cyclin D1. J. Neurosci. 26 (2006) 5402-5410
26. Takayama S., Rogatsky I., Schwarcz L.E., and Darimont B.D. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. J. Biol. Chem. 281 (2006) 17856-17863
27. Bladh L.G., Liden J., Pazirandeh A., Rafter I., Dahlman-Wright K., Nilsson S., and Okret S. Identification of target genes involved in the antiproliferative effect of glucocorticoids reveals a role for nuclear factor-(kappa)B repression. Mol. Endocrinol. 19 (2005) 632-643
28. Li Z., Chen Y., Cao D., Wang Y., Chen G., Zhang S., and Lu J. Glucocorticoid up-regulates transforming growth factor-beta (TGF-beta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells. Endocrinology 147 (2006) 5259-5267
29. Ogias D., Bitencourt B., Alvares E.P., and Gama P. Corticosteroids induce the differential expression of TGFbeta isoforms, receptors and signaling in the gastric mucosa of suckling rats. Regul. Pept. 135 (2006) 17-22
30. Reyes-Moreno C., Frenette G., Boulanger J., Lavergne E., Govindan M.V., and Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 26 (1995) 260-269
31. Gold L.I. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit. Rev. Oncog. 10 (1999) 303-360
32. Dennler S., Goumans M.J., ten P., and Dijke. Transforming growth factor beta signal transduction. J. Leukoc. Biol. 71 (2002) 731-740
33. Canguilhem B., Pradines A., Baudouin C., Boby C., Lajoie-Mazenc I., Charveron M., and Favre G. RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling. J. Biol. Chem. 280 (2005) 43257-43263
34. Jiang K., Delarue F.L., and Sebti S.M. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 23 (2004) 1136-1145
35. Rodriguez P.L., Sahay S., Olabisi O.O., and Whitehead I.P. ROCK I-mediated activation of NF-kappaB by RhoB. Cell Signal. 19 (2007) 2361-2369
36. Chen Z., Sun J., Pradines A., Favre G., Adnane J., and Sebti S.M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275 (2000) 17974-17978
37. Huang M., and Prendergast G.C. RhoB in cancer suppression. Histol. Histopathol. 21 (2006) 213-218
38. Mazieres J., Antonia T., Daste G., Muro-Cacho C., Berchery D., Tillement V., Pradines A., Sebti S., and Favre G. Loss of RhoB expression in human lung cancer progression. Clin. Cancer Res. 10 (2004) 2742-2750
39. Chen Y.X., Li Z.B., Diao F., Cao D.M., Fu C.C., and Lu J. Up-regulation of RhoB by glucocorticoids and its effects on the cell proliferation and NF-kappaB transcriptional activity. J. Steroid Biochem. Mol. Biol. 101 (2006) 179-187